Novartis COX-2 is Prexige
Executive Summary
Novartis' COX-189 brand name is Prexige (lumiracoxib). An NDA filing for the COX-2 inhibitor is planned for late 2002 (1"The Pink Sheet" Nov. 12, 2001, p. 32)...
You may also be interested in...
Novartis COX-189 TARGET Study Will Assess CV Safety Of COX-2 Inhibitor
Novartis' long-term COX-2 inhibitor safety study will be sufficiently large to provide "clear" evidence of the cardiovascular safety of COX-189, Clinical R&D Head James Shannon told analysts in New York City Oct. 30
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.